Chunyan Yan

Yantai, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States.

Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States.

Journal: Human vaccines & immunotherapeutics

Published: August 22, 2026

Cost-effectiveness of sugemalimab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced oesophageal squamous cell carcinoma in China.

Cost-effectiveness of sugemalimab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced oesophageal squamous cell carcinoma in China.

Journal: BMJ open

Published: February 24, 2026

Cost-effectiveness analysis of sugemalimab plus chemotherapy for the first-line treatment of advanced gastric cancer or gastroesophageal junction cancer.

Cost-effectiveness analysis of sugemalimab plus chemotherapy for the first-line treatment of advanced gastric cancer or gastroesophageal junction cancer.

Journal: Human vaccines & immunotherapeutics

Published: January 12, 2026

Cost-effectiveness analysis of penpulimab combined with paclitaxel and carboplatin as a first-line treatment for metastatic squamous non-small cell lung cancer in China.

Cost-effectiveness analysis of penpulimab combined with paclitaxel and carboplatin as a first-line treatment for metastatic squamous non-small cell lung cancer in China.

Journal: BMJ open

Published: March 03, 2025

Cost-effectiveness of benmelstobart and anlotinib plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer in China.

Cost-effectiveness of benmelstobart and anlotinib plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer in China.

Journal: Scientific reports

Published: August 15, 2024

TClC effectively suppresses the growth and metastasis of NSCLC via polypharmacology.

TClC effectively suppresses the growth and metastasis of NSCLC via polypharmacology.

Journal: Bioactive materials

Published: June 29, 2024

PD-1 inhibitors in advanced esophageal squamous cell carcinoma: a survival analysis of reconstructed patient-level data.

PD-1 inhibitors in advanced esophageal squamous cell carcinoma: a survival analysis of reconstructed patient-level data.

Journal: Frontiers in pharmacology

Published: March 28, 2024

An L-theanine derivative targets against SARS-CoV-2 and its Delta and Omicron variants.

An L-theanine derivative targets against SARS-CoV-2 and its Delta and Omicron variants.

Journal: Heliyon

Published: January 20, 2022

Showing 1-8 of 8

Last Updated: 09/26/2026